Curium, a world leader in nuclear medicine, announced today that it has expanded its existing partnership with Institute of ...

Curium introduces innovative 18F-PSMA PET radiopharmaceutical, Pylclari to treat prostate cancer in Estonia, Finland, Latvia, & Sweden: Paris, France Wednesday, January 29, 2025, ...

Portsmouth’s leading workspace, has announced a new lettings agreement with Curium - the world-leading nuclear medicine ...

Curium, a world leader in nuclear medicine, today announced that in Estonia, Finland, Latvia, and Sweden, PYLCLARI® is now ...

After a breakdown in US-Russia relations, Riken finds itself ahead of its rivals. And Lawrence Berkeley National Laboratory ...

T his morning, the United States Supreme Court upheld the TikTok ban in a 9-0, per curium decision. The Court unanimously ...

Telix, a commercial-stage biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic (‘theranostic’) radiopharmaceuticals, announces that it has entered ...

The agreement also includes a strategic contract manufacturing agreement appointing Curium as the manufacturer of the product for Telix. Scintimun is an internationally approved product [2] and ...

Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has entered into an agreement with Curium Pharma for the transfer of marketing and distribution rights ...

MELBOURNE, Australia and LIÈGE, Belgium, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has entered into an agreement ...